Autism and cancer risk

Autism Research

Volumn 4, Issue 4, 2011, Pages 302-310

  Crespi, B ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TESTOSTERONE; TUBERIN;

ALZHEIMER DISEASE; AUTISM; CANCER GROWTH; CANCER RISK; CHILDHOOD CANCER; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; EPIGENETICS; FRAGILE X SYNDROME; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC PREDISPOSITION; HUMAN; MEDLINE; MENTAL DEFICIENCY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TUMOR GENE; TUMOR SUPPRESSOR GENE;

AUTISTIC DISORDER; COMORBIDITY; HUMANS; NEOPLASMS; RISK;

EID: 80055041133     PISSN: 19393792     EISSN: 19393806     Source Type: Journal    
DOI: 10.1002/aur.208     Document Type: Review

References (122)

1. Agarwal, R., Carey, M., Hennessy, B., & Mills, G.B. (2010). PI3K pathway-directed therapeutic strategies in cancer. Current Opinion in Investigational Drugs, 11, 615-628.
2. Anderson, G.M., Jacobs-Stannard, A., Chawarska, K., Volkmar, F.R., & Kliman, H.J. (2007). Placental trophoblast inclusions in autism spectrum disorder. Biological Psychiatry, 61, 487-491.
3. Badcock, C., & Crespi, B. (2006). Imbalanced genomic imprinting in brain development: An evolutionary basis for the aetiology of autism. Journal of Evolutionary Biology, 19, 1007-1032.
4. Baik, I., Devito, W.J., Ballen, K., Becker, P.S., Okulicz, W., et al. (2005). Association of fetal hormone levels with stem cell potential: Evidence for early life roots of human cancer. Cancer Research, 65, 358-363.
5. Bajaj, A., Driver, J.A., & Schernhammer, E.S. (2010). Parkinson's disease and cancer risk: A systematic review and meta-analysis. Cancer Causes and Control, 21, 697-707.
6. Barak, Y., Achiron, A., Mandel, M., Mirecki, I., & Aizenberg, D. (2005). Reduced cancer incidence among patients with schizophrenia. Cancer, 104, 2817-2821.
7. Baron-Cohen, S. (2002). The extreme male brain theory of autism. Trends in Cognitive Sciences, 6, 248-254.
8. Baron-Cohen, S., Knickmeyer, R.C., & Belmonte, M.K. (2005). Sex differences in the brain: Implications for explaining autism. Science, 310, 819-823.
9. Behrens, M.I., Lendon, C., & Roe, C.M. (2009). A common biological mechanism in cancer and Alzheimers disease? Current Alzheimer Research, 6, 196-204.
10. Belmonte, M.K., & Bourgeron, T. (2006). Fragile X syndrome and autism at the intersection of genetic and neural networks. Nature Neuroscience, 9, 1221-1225.
11. Bourgeron, T. (2009). A synaptic trek to autism. Current Opinion in Neurobiology, 19, 231-234.
12. Bunney, T.D., & Katan, M. (2010). Phosphoinositide signalling in cancer: Beyond PI3K and PTEN. Nature Reviews Cancer, 10, 342-352.
13. Burdick, K.E., DeRosse, P., Kane, J.M., Lencz, T., & Malhotra, A.K. (2010). Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. American Journal of Psychiatry, 167, 436-443.
14. Butler, M.G., Dasouki, M.J., Zhou, X.P., Talebizadeh, Z., Brown, M., et al. (2005). Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. Journal of Medical Genetics, 42, 318-321.
15. Campbell, D.B., Sutcliffe, J.S., Ebert, P.J., Militerni, R., Bravaccio, C., et al. (2006). A genetic variant that disrupts MET transcription is associated with autism. Proceedings of the National Academy of Sciences of the USA, 103, 16834-16839.
16. Caricasole, A., Bakker, A., Copani, A., Nicoletti, F., Gaviraghi, G., & Terstappen, G.C. (2005). Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Bioscience Reports, 25, 309-327.
17. Catts, V.S., Catts, S.V., Mcgrath, J.J., Féron, F., Mclean, D., et al. (2006). Apoptosis and schizophrenia: A pilot study based on dermal fibroblast cell lines. Schizophrenia Research, 84, 20-28.
18. Catts, V.S., Catts, S.V., O'Toole, B.I., & Frost, A.D. (2008). Cancer incidence in patients with schizophrenia and their first-degree relatives-A meta-analysis. Acta Psychiatrica Scandinavica, 117, 323-336.
19. Chakrabarti, B., Dudbridge, F., Kent, L., Wheelwright, S., Hill-Cawthorne, G., et al. (2009). Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and Asperger syndrome. Autism Research, 2, 157-177.
20. Chen, da C., Wang, J., Wang, B., Yang, S.C., Zhang, C.X., et al. (2009). Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: Relationship to clinical phenotypes. Psychopharmacology (Berlin), 207, 375-380.
21. Ciuffreda, L., Di Sanza, C., Incani, U.C., & Milella, M. (2010). The mTOR pathway: A new target in cancer therapy. Current Cancer Drug Targets, 10, 484-495.
22. Cohen, M., Dembling, B., & Schorling, J. (2002). The association between schizophrenia and cancer: A population-based mortality study. Schizophrenia Research, 57, 139-146.
23. Connolly, A.M., Chez, M., Streif, E.M., Keeling, R.M., Golumbek, P.T., et al. (2006). Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biological Psychiatry, 59, 354-363.
24. Costa-Mattioli, M., Sossin, W.S., Klann, E., & Sonenberg, N. (2009). Translational control of long-lasting synaptic plasticity and memory. Neuron, 61, 10-26.
25. Cotter, D., Kerwin, R., Al-Sarraji, S., Brion, J.P., Chadwich, A., et al. (1998). Abnormalities of WNT signalling in schizophrenia-Evidence for neurodevelopmental abnormality. Neuroreport, 9, 1379-1383.
26. Courchesne, E., & Pierce, K. (2005). Brain overgrowth in autism during a critical time in development: Implications for frontal pyramidal neuron and interneuron development and connectivity. International Journal of Developmental Neuroscience, 23, 153-170.
27. Crespi, B., & Badcock, C. (2008). Psychosis and autism as diametrical disorders of the social brain. Behavioral and Brain Sciences, 31, 241-261; discussion 261-320.
28. Cui, D.H., Jiang, K.D., Jiang, S.D., Xu, Y.F., & Yao, H. (2005). The tumor suppressor Adenomatous Polyposis Coli gene is associated with susceptibility to schizophrenia. Molecular Psychiatry, 10, 669-677.
29. Curatolo, P., Napolioni, V., & Moavero, R. (2010). Autism spectrum disorders in tuberous sclerosis: Pathogenetic pathways and implications for treatment. Journal of Child Neurology, 25, 873-880.
30. Dalton, S.O., Mellemkjaer, L., Thomassen, L., Mortensen, P.B., & Johansen, C. (2005). Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophrenia Research, 75, 315-324.
31. D'Amelio, M., Ricci, I., Sacco, R., Liu, X., Dagruma, L., et al. (2005). Paraoxonase gene variants are associated with autism in North America, but not in Italy: Possible regional specificity in gene-environment interactions. Molecular Psychiatry, 10, 1006-1016.
32. De Ferrari, G.V., & Moon, R.T. (2006). The ups and downs of WNT signaling in prevalent neurological disorders. Oncogene, 25, 7545-7553.
33. Dicicco-Bloom, E., Lord, C., Zwaigenbaum, L., Courchesne, E., Dager, S.R., et al. (2006). The developmental neurobiology of autism spectrum disorder. Journal of Neuroscience, 26, 6897-6906.
34. Dissanayake, C., Bui, Q.M., Huggins, R., & Loesch, D.Z. (2006). Growth in stature and head circumference in high-functioning autism and asperger disorder during the first 3 years of life. Development and Psychopathology, 18, 381-393.
35. Durany, N., & Thome, J. (2004). Neurotrophic factors and the pathophysiology of schizophrenic psychoses. European Psychiatry, 19, 326-337.
36. Eggerman, T. (2009). Silver-Russell and Beckwith-Wiedemann syndromes: opposite (epi)mutations in 11p15 results in opposite clinical pictures. Hormone Research, 71, Suppl. 2, 30-35.
37. Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M., & Gogos, J.A. (2004). Convergent evidence for impaired Akt1-Gsk3b signaling in schizophrenia. Nature Genetics, 36, 131-137.
38. Endersby, R., & Baker, S.J. (2008). PTEN signaling in brain: Neuropathology and tumorigenesis. Oncogene, 5416-5430.
39. Engelman, J.A., Luo, J., & Cantley, L.C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics, 7, 606-619.
40. Eriksson, P.S. (2006). Schizophrenia-A stem cell disorder. Experimental Neurology, 199, 26-27.
41. Feinberg, A.P., & Tycko, B. (2004). The history of cancer epigenetics. Nature Reviews Cancer, 4, 143-153.
42. Fischer, P. M. (2009). Cap in hand: Targeting eIF4E. Cell Cycle, 8, 2535-2541.
43. Freyberg, Z., Ferrando, S.J., & Javitch, J.A. (2010). Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. American Journal of Psychiatry, 167, 388-396.
44. Gao, X., Mohsin, S.K., Gatalica, Z., Fu, G., Sharma, P., & Nawaz, Z. (2005). Decreased expression of E6-associated protein in breast and prostate carcinomas. Endocrinology, 146, 1707-1712.
45. Ghayad, S.E., & Cohen, P.A. (2010). Inhibitors of the PI3K/Akt/mTOR pathway: New hope for breast cancer patients. Recent Patents on Anticancer Drug Discovery, 5, 29-57.
46. Glantz, L.A., Gilmore, J.H., Lieberman, J.A., & Jarskog, L.F. (2006). Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research, 81, 47-63.
47. Glessner, J.T., Wang, K., Cai, G., Korvatska, O., Kim, C.E., et al. (2009). Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature, 459, 569-573.
48. Goldacre, M.J., Kurina, L.M., Wotton, C.J., Yeates, D., & Seagroat, V. (2005). Schizophrenia and cancer: An epidemiological study. British Journal of Psychiatry, 187, 334-338.
49. Greer, J.M., & Wynshaw-Boris, A. (2006). Pten and the brain: Sizing up social interaction. Neuron, 50, 343-345.
50. Grillo, R.W., Ottoni, G.L., Leke, R., Souza, D.O., Portela, L.V., & Lara, D.R. (2007). Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research, 41, 31-35.
51. Gunnell, D., & Holly, J.M. (2004). Hypothesis: Do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia. Schizophrenia Research, 71, 191-193.
52. Hagerman, R.J. (2006). Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. Journal of Developmental and Behavioral Pediatrics, 27, 63-74.
53. Hanlon, F.M., Weisend, M.P., Hamilton, D.A., Jones, A.P., Thoma, R.J., et al. (2006). Impairment on the hippocampal-dependent virtual Morris water task in schizophrenia. Schizophrenia Research, 87, 67-80.
54. Happé, F., Ronald, A., & Plomin, R. (2006). Time to give up on a single explanation for autism. Nature Neuroscience, 9, 1218-1220.
55. Herman, G.E., Butter, E., Enrile, B., Pastore, M., Prior, T.W., Sommer, A. (2007). Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. American Journal of Medical Genetics Part A, 143A, 589-593.
56. Hernandez, L., Kozlov, S., Piras, G., & Stewart, C.L. (2003). Paternal and maternal genomes confer opposite effects on proliferation, cell-cycle length, senescence, and tumor formation. Proceedings of the National Academy of Sciences of the USA, 100, 13344-13349.
57. Hernandez, R.N., Feinberg, R.L., Vaurio, R., Passanante, N.M., Thompson, R.E., & Kaufmann, W.E. (2009). Autism spectrum disorder in Fragile X syndrome: A longitudinal evaluation. American Journal of Medical Genetics Part A, 149A, 1125-1137.
58. Hranilovic, D., Bujas-Petkovic, Z., Vragovic, R., Vuk, T., Hock, K., & Jernej, B. (2007). Hyperserotonemia in adults with autistic disorder. Journal of Autism and Developmental Disorders, 37, 1934-1940.
59. Hoeffer, C.A., & Klann, E. (2010). mTOR signaling: At the crossroads of plasticity, memory and disease. Trends in Neuroscience, 33, 67-75.
60. Hu, Y., Sun, C.Y., Wang, H.F., Guo, T., Wei, W.N., et al. (2006). Brain-derived neurotrophic factor promotes growth and migration of multiple myeloma cells. Cancer Genetics and Cytogenetics, 169, 12-20.
61. Ingudomnukul, E., Baron-Cohen, S., Wheelwright, S., & Knickmeyer, R. (2007). Elevated rates of testosterone-related disorders in women with autism spectrum conditions. Hormones and Behavior, 51, 597-604.
62. Janssens, N., Janicot, M., & Perera, T. (2006). The Wnt-dependent signaling pathways as target in oncology drug discovery. Investigational New Drugs 24, 263-280.
63. Jelinic, P., & Shaw, P. (2007). Loss of imprinting and cancer. Journal of Pathology, 211, 261-268.
64. Jiang, Y.H., Sahoo, T., Michaelis, R.C., Bercovich, D., Bressler, J. et al. (2004). A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. American Journal of Medical Genetics, 131, 1-10.
65. Kale, A., Joshi, S., Pillai, A., Naphade, N., Raju, M., et al. (2009). Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients. Schizophrenia Research, 115, 209-214.
66. Kalkman, H.O. (2006). The role of the phosphatidylinositide 3-kinase-protein kinase b pathway in schizophrenia. Pharmacology & Therapeutics, 110, 117-134.
67. Kao, H.T., Buka, S.L., Kelsey, K.T., Gruber, D.F., & Porton, B. (2010). The correlation between rates of cancer and autism: An exploratory ecological investigation. PLoS One, 5, e9372.
68. Kelleher III, R.J., & Bear, M.F. (2008). The autistic neuron: Troubled translation? Cell, 135, 401-406.
69. Kent, L., Bowdin, S., Kirby, G.A., Cooper, W.N., & Maher, E.R. (2008). Beckwith Weidemann syndrome: A behavioral phenotype-genotype study. American Journal of Medical Genetics Part B Neuropsychiatric Genetics, 147B, 1295-1297.
70. Kim, R.H., & Mak, T.W. (2006). Tumours and tremors: How PTEN regulation underlies both. British Journal of Cancer, 94, 620-624.
71. Knickmeyer, R.C., & Baron-Cohen, S. (2006). Fetal testosterone and sex differences in typical social development and in autism. Journal of Child Neurology, 21, 825-845.
72. Kurmasheva, R.T., & Houghton, P.J. (2006). IGF-I mediated survival pathways in normal and malignant cells. Biochimica et Biophysica Acta, 1766, 1-22.
73. Kwon, C.H., Luikart, B.W., Powell, C.M., Zhou, J., Matheny, S.A., et al. (2006). Pten regulates neuronal arborization and social interaction in mice. Neuron, 50, 377-388.
74. Lainhart, J.E., Bigler, E.D., Bocian, M., Coon, H., Dinh, E., et al. (2006). Head circumference and height in autism: A study by the collaborative program of excellence in autism. American Journal of Medical Genetics, 140, 2257-2274.
75. Levav, I., Lipshitz, I., Novikov, I., Pugachova, I., Kohn, R., et al. (2007). Cancer risk among parents and siblings of patients with schizophrenia. British Journal of Psychiatry, 190, 156-161.
76. Li, F., Tiede, B., Massague, J., & Kang, Y. (2007). Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Research, 17, 3-14.
77. Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A., & Lonnqvist, J. (2001). Incidence of cancer among persons with schizophrenia and their relatives. Archives of General Psychiatry, 58, 573-580.
78. Maehle, B.O., Vatten, L.J., & Tretli, S. (2010). Birth length and weight as predictors of breast cancer prognosis. BMC Cancer, 10, 115.
79. Marui, T., Hashimoto, O., Nanba, E., Kato, C., Tochigi, M., et al. (2004). Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 131B, 43-47.
80. Mbarek, O., Marouillat, S., Martineau, J., Barthelemy, C., Muh, J.P., & Andres, C. (1999). Association study of the NF1 gene and autistic disorder. American Journal of Medical Genetics, 88, 729-732.
81. McBride, K.L., Varga, E.A., Pastore, M.T., Prior, T.W., Manickam, K., et al. (2010). Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Research, 3, 137-141.
82. McCaffery, P., & Deutsch, C.K. (2005). Macrocephaly and the control of brain growth in autistic disorders. Progress in Neurobiology, 77, 38-56.
83. McCall, T., Chin, S.S., Salzman, K.L. & Fults, D.W. (2006). Tuberous sclerosis: A syndrome of incomplete tumor suppression. Neurosurgical Focus, 20, E3.
84. Mills, J.l., Hediger, M.l., Molloy, C.A., Chrousos, G.P., Manning-Courtney, P., et al. (2007). Elevated levels of growth-related hormones in autism and autism spectrum disorder. Clinical Endocrinology (Oxford), 67, 230-237.
85. Mitrunen, K., & Hirvonen, A. (2003). Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutation Research, 544, 9-41.
86. Miyazaki, K., Narita, N., Sakuta, R., Miyahara, T., Naruse, H., et al. (2004). Serum neurotrophin concentrations in autism and mental retardation: A pilot study. Brain and Development, 26, 292-295.
87. Moberg, P.J., Arnold, S.E., Doty, R.L., Gur, R.E., Balderston, C.C., et al. (2006). Olfactory functioning in schizophrenia: Relationship to clinical, neuropsychological, and volumetric MRI measures. Journal of Clinical and Experimental Neuropsychology, 28, 1444-1461.
88. Moises, H.W., Zoega, T., & Gottesman, I.I. (2002). The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry, 2, 8.
89. Morris, L.G., Veeriah, S., & Chan, T.A. (2010). Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene, 29, 3453-3464.
90. Mraz, K.D., Dixon, J., Dumont-Mathieu, T., & Fein, D. (2009). Accelerated head and body growth in infants later diagnosed with autism spectrum disorders: A comparative study of optimal outcome children. Journal of Child Neurology, 24, 833-845.
91. Neves-Pereira, M., Müller, B., Massie, D., Williams, J.H., O'Brien, P.C., et al. (2009). Deregulation of EIF4E: A novel mechanism for autism. Journal of Medical Genetics, 46, 759-765.
92. Ni, X., Trakalo, J., Valente, J., Azevedo, M.H., Pato, M.T., et al. (2005). Human P53 tumor suppressor gene (TP53) and schizophrenia: Case-control and family studies. Neuroscience Letters, 388, 173-178.
93. Plun-Favreau, H., Lewis, P.A., Hardy, J., Martins, L.M. & Wood, N.W. (2010). Cancer and neurodegeneration: Between the devil and the deep blue sea. PLoS Genetics, 6, e1001257.
94. Reif, A., Fritzen, S., Finger, M., Strobel, A., Lauer, M.A., et al. (2006). Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Molecular Psychiatry, 11, 514-522.
95. Richter, J.D., & Klann, E. (2009). Making synaptic plasticity and memory last: Mechanisms of translational regulation. Genes and Development 23, 1-11.
96. Roe, C.M., Behrens, M.I., Xiong, C., Miller, J.P., & Morris, J.C. (2005). Alzheimer disease and cancer. Neurology, 64, 895-898.
97. Roe, C.M., Fitzpatrick, A.L., Xiong, C., Sieh, W., Kuller, L., et al. (2010). Cancer linked to Alzheimer disease but not vascular dementia. Neurology, 74, 106-112.
98. Rosales-Reynoso, M.A., Ochoa-Hernández, A.B., Aguilar-Lemarroy, A., Jave-Suárez, L.F., Troyo-Sanromán, R., & Barros-Núñez, P. (2010). Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients. Archives of Medical Research, 41, 110-118.
99. Rosner, M., Hanneder, M., Siegel, N., Valli, A., Fuchs, C., & Hengstschläger, M. (2008). The mTOR pathway and its role in human genetic diseases. Mutation Research, 659, 284-292.
100. Rump, P., Zeegers, M.P., & Van Essen, A.J. (2005). Tumor risk in Beckwith-Wiedemann syndrome: A review and meta-analysis. American Journal of Medical Genetics, 136, 95-104.
101. Samaco, R.C., Hogart, A., & Lasalle, J.M. (2005). Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A And GABRB3. Human Molecular Genetics, 14, 483-492.
102. Schultz-Pedersen, S., Hasle, H., Olsen, H., et al. (2001). Evidence of decreased risk of cancer in individuals with Fragile X. American Journal of Medical Genetics, 103, 226-230.
103. Serajee, F.J., Nabi, R., Zhong, H., & Mahbubul Huq, A.H.M. (2003). Association of INPP1, PIK3CG, and TSC2 gene variants with autistic disorder: Implications for phosphatidylinositol signalling in autism. Journal of Medical Genetics, 40, E119.
104. Sharma, A., Hoeffer, C.A., Takayasu, Y., Miyawaki, T., McBride, S.M., et al. (2010). Dysregulation of mTOR signaling in fragile X syndrome. Journal of Neuroscience, 30, 694-702.
105. Shavelle, R.M., Strauss, D.J., & Pickett, J. (2001). Causes of death in autism. Journal of Autism and Developmental Disorders, 31, 569-576.
106. Silva, I.S., De Stavola, B., McCormack, V., & Collaborative Group on Pre-Natal Risk Factors and Subsequent Risk of Breast Cancer. (2008). Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Medicine, 5, e193.
107. Silva, A.J., & Ehninger, D. (2009). Adult reversal of cognitive phenotypes in neurodevelopmental disorders. Journal of Neurodevelopmental Disorders, 1, 150-157.
108. Sohur, U.S., Emsley, J.G., Mitchell, B.D., & Macklis, J.D. (2006). Adult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells. Philosophical Transactions of the Royal Society of London. Series B. Biological Sciences, 361, 1477-1497.
109. Stopkova, P., Saito, T., Papolos, D.F., Vevera, J., Paclt, I., et al. (2004). Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. Biological Psychiatry, 55, 981-988.
110. Sugie, Y., Sugie, H., Fukuda, T., & Ito, M. (2005). Neonatal factors in infants with autistic disorder and typically developing infants. Autism, 9, 487-94.
111. Szudek, J., Evans, D.G., & Friedman, J.M. (2003). Patterns of associations of clinical features in neurofibromatosis 1 (NF1). Human Genetics, 112, 289-297.
112. Tamimi, R.M., Eriksson, L., Lagiou, P., Czene, K., Ekbom, A., et al. (2010). Birth weight and mammographic density among postmenopausal women in Sweden. International Journal of Cancer, 126, 985-991.
113. Tsai, S.J. (2005). Is autism caused by early hyperactivity of brain-derived neurotrophic factor? Medical Hypotheses, 65, 79-82.
114. Tycko, B., & Morison, I.M. (2002). Physiological functions of imprinted genes. Journal of Cell Physiology, 192, 245-258.
115. Ukraintseva, S.V., Arbeev, K.G., Akushevich, I., Kulminski, A., Arbeeva, L., et al. (2010). Trade-offs between cancer and other diseases: Do they exist and influence longevity. Rejuvenation Research, 13, 387-396.
116. Vaccarino, F.M., & Smith, K.M. (2009). Increased brain size in autism-What it will take to solve a mystery. Biological Psychiatry, 66, 313-315.
117. Varga, E.A., Pastore, M., Prior, T., Herman, G.E., & Mcbride, K.l. (2009). The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genetics in Medicine, 11, 111-117.
118. Wassink, T.H., Piven, J., Vieland, V.J., Huang, J., Swiderski, R.E., et al. (2001). Evidence supporting WNT2 as an autism susceptibility gene. American Journal of Medical Genetics, 105, 406-413.
119. Weickert, C.S., Hyde, T.M., Lipska, B.K., Herman, M.M., Weinberger, D.R., & Kleinman, J.E. (2003). Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Molecular Psychiatry, 8, 592-610.
120. West, A.B., Dawson, V.L., & Dawson, T.M. (2005). To die or grow: Parkinson's disease and cancer. Trends in Neuroscience, 28, 348-352.
121. Zhou, X.L., Eriksson, U., Werelius, B., Kressner, U., Sun, X.F., & Lindblom, A. (2004). Definition of candidate low risk APC alleles in a Swedish population. International Journal of Cancer, 110, 550-557.
122. Zhou, X.L., Giacobini, M., Anderlid, B.M., Anckarsater, H., Omrani, D., et al. (2007). Association of adenomatous polyposis coli (APC) gene polymorphisms with autism spectrum disorder (ASD). American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 144B, 351-354.